Biotechnology and pharmaceutical companies seeking to train employees, or even to create their own "online university" can now partner with The Pharmaceutical Institute (PI, Raleigh, NC, www.pharmainstitute.com).
Biotechnology and pharmaceutical companies seeking to train employees, or even to create their own “online university” can now partner with The Pharmaceutical Institute (PI) of Raleigh, NC (www.pharmainstitute.com). PI, a subsidiary of the consulting firm Campbell Alliance, launched its “Corporate Academy Program” in June. The program allows industry clients to implement a training infrastructure without having to set up their own learning management system (LMS).
“We realized there are a lot of small companies or work groups within large companies that have an interest in training, but they don’t have the resources to commit to evaluating, purchasing, and implementing an LMS, maintaining that system, developing new content, or going out and surveying the universe of available content and keep it running for their employees,” said Dan Blue, executive director of PI. “We can set it all up for them with a turn-key solution that allows users to get up and running fairly quickly.”
Clients have the option of using their own proprietary educational material, using PI’s resources, using material licensed by PI from outside vendors, or any combination of all three to customize an educational program for employees.
Services available include:
Although the system originally was designed for small- to mid-size companies, Craig Dunkley, vice president of marketing for Campbell Alliance, says the program’s flexibility also makes it suitable for work groups within large corporations. “If individual work groups within [a large pharmaceutical] company come to us and want to work on developing a corporate academy, we’re certainly happy to do that,” he said.
Cost to the client for participating in the Corporate Academy Program is determined by the number of participants and the amount of educational content, per the terms of each individual agreement.
–Pam Holland-Moritz
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.